● AI Equity Research · Healthcare

AbCellera Biologics Inc. (ABCL)

AI stock analysis · Biotechnology · Last analyzed Jul 8, 2026

Compass Score

3.0/5

Call

Hold

Price

$7.24

AI Target

$10.50 +45.0%

AI Analyst Summary

AbCellera Biologics is a clinical-stage antibody discovery platform company posting exceptional 96.3% revenue growth YoY, driven by expanding partnerships and royalty-generating programs across its drug discovery pipeline. The unanimous Strong Buy consensus among 9 analysts reflects high conviction in the platform's long-term value creation potential as partner programs advance toward commercialization. The primary risk is the company's loss-making status, with no clear near-term profitability inflection, exposing investors to ongoing cash burn and dilution risk.

Catalysts

Partner drug approvals or late-stage clinical readouts from AbCellera's royalty-bearing programs could unlock material recurring revenue streams in the next 1–2 quarters.
Continued acceleration in new partnership agreements and licensing deals, building on the 96.3% revenue growth trend into the next fiscal year.
Potential positive surprise in Q4 or Q1 earnings if revenue from royalties and milestones continues to outpace consensus estimates, reinforcing analyst price targets near $10.50.

Risks

Sustained cash burn with a negative forward P/E of -10.1x raises dilution risk if the company needs to raise additional capital through equity offerings, pressuring the share price.
Heavy revenue concentration risk — if one or more key platform partnerships are delayed, terminated, or fail in clinical trials, the 96.3% revenue growth rate could reverse sharply.
With only 4 quarters of EPS history and no consensus rating on the inverted scale, execution risk remains elevated; any earnings miss could trigger outsized selloffs given the stock's already elevated volatility (down 5.85% in a single session).

Fundamentals

Pe N/A (loss-making) · 1.0/5

Company is currently loss-making with no trailing P/E available and a negative forward P/E of -10.1x, indicating no near-term path to profitability on current estimates.

Peg N/A · 3.0/5

PEG ratio is unavailable given the lack of positive earnings. Defaulting to neutral score of 3, though the strong 96.3% revenue growth provides some offset to the absence of earnings-based valuation.

Analyst Rating Strong Buy consensus (1.0) · 5.0/5

9 Buy ratings, 0 Hold, 0 Sell across 9 analysts — a unanimously bullish stance. Consensus maps to a strong buy signal, capped at 5 given the clean sweep. Exceeds the 5-analyst minimum threshold.

Earnings Trend Revenue +96.3% YoY; EPS trend N/A · 3.0/5

Revenue growth of 96.3% YoY is exceptional and signals strong commercial momentum, but the company remains unprofitable with no earnings growth figure available. Score reflects the strong top-line trajectory tempered by ongoing losses.

Price Target Beat 3 of 4 quarters beat · 2.0/5

EPS beat rate of 3 of 4 quarters over recent history is below average relative to the 5-of-8 benchmark for a score of 4. Only 4 quarters of data available, so this is scored conservatively at 2 given the limited history and below-median beat rate implied.

Management Mixed — strong revenue execution, inconsistent EPS delivery · 3.0/5

Unanimous analyst bullishness suggests confidence in the leadership team's strategic direction and pipeline development. However, ongoing losses and a limited EPS beat history temper the management score. Capital allocation remains under scrutiny in a cash-burn environment.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.